Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: AMRX ANIP ARDX ASRT ASND EYPT HRTX LXRX PCRX PTGX

| Held by: IJR VTI IWM VXF SPSM AVUV IJT IWO PJP CALF

Index	RUT	P/E	29.10	EPS (ttm)	1.61	Insider Own	3.32%	Shs Outstand	31.60M	Perf Week	-1.60%
Market Cap	1.48B	Forward P/E	5.43	EPS next Y	8.61	Insider Trans	-13.72%	Shs Float	30.56M	Perf Month	2.66%
Enterprise Value	2.11B	PEG	1.23	EPS next Q	2.14	Inst Own	121.19%	Short Float	15.69%	Perf Quarter	10.52%
Income	58.44M	P/S	1.95	EPS this Y	15.82%	Inst Trans	4.02%	Short Ratio	9.56	Perf Half Y	29.36%
Sales	757.07M	P/B	5.38	EPS next Y	15.26%	ROA	3.60%	Short Interest	4.79M	Perf YTD	0.97%
Book/sh	8.70	P/C	4.83	EPS next 5Y	4.41%	ROE	22.96%	52W High	50.79 -7.95%	Perf Year	53.18%
Cash/sh	9.67	P/FCF	5.11	EPS past 3/5Y	0.01% -	ROIC	5.10%	52W Low	23.23 101.25%	Perf 3Y	74.77%
Dividend Est.	-	EV/EBITDA	5.42	Sales past 3/5Y	31.63% 16.31%	Gross Margin	57.22%	Volatility	3.14% 3.85%	Perf 5Y	80.15%
Dividend TTM	-	EV/Sales	2.78	EPS Y/Y TTM	-32.79%	Oper. Margin	21.47%	ATR (14)	1.67	Perf 10Y	165.17%
Dividend Ex-Date	-	Quick Ratio	1.27	Sales Y/Y TTM	26.34%	Profit Margin	7.72%	RSI (14)	50.11	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	1.36	EPS Q/Q	213.22%	SMA20	0.40%	Beta	0.65	Target Price	53.67
Payout	0.00%	Debt/Eq	3.41	Sales Q/Q	31.42%	SMA50	-1.30%	Rel Volume	0.61	Prev Close	46.28
Employees	357	LT Debt/Eq	3.17	Earnings	Nov 06 BMO	SMA200	25.20%	Avg Volume	501.57K	Price	46.75
IPO	May 07, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.97% 10.70%	Trades		Volume	309,532	Change	1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$58
Jan-10-25	Upgrade	Needham	Hold → Buy	$46
Jul-30-24	Upgrade	H.C. Wainwright	Neutral → Buy	$47
Jun-07-24	Upgrade	Jefferies	Hold → Buy	$41 → $44
May-10-24	Downgrade	Piper Sandler	Overweight → Neutral	$39
May-10-24	Downgrade	Needham	Buy → Hold
Jan-04-24	Downgrade	Jefferies	Buy → Hold	$30 → $37
Aug-25-23	Reiterated	Needham	Buy	$35 → $36
May-02-23	Resumed	Jefferies	Buy	$30
Aug-08-22	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-15-22	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$18 → $26
Aug-06-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-11-21	Reiterated	H.C. Wainwright	Buy	$29 → $33
Jul-14-20	Initiated	BWS Financial	Sell	$8
May-27-20	Initiated	Guggenheim	Neutral
Feb-19-20	Resumed	Jefferies	Buy	$43
Oct-30-19	Reiterated	Needham	Buy	$33 → $25
May-03-19	Resumed	H.C. Wainwright	Buy	$23
Apr-12-19	Resumed	Janney	Buy	$29
Mar-20-19	Initiated	SunTrust	Hold	$22

Show Previous Ratings

Jan-15-26 08:00AM	Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire)
Jan-12-26 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks) +5.73%
Jan-08-26 08:00AM	Collegium Provides 2026 Financial Guidance and Business Update (GlobeNewswire)
Jan-05-26 09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:22AM	Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio (Zacks)
01:04PM	Loading…
Dec-31-25 01:04PM	Why You Should Add Encompass Health to Your Portfolio Now (Zacks)
11:24AM	Here's Why You Should Retain Community Health Stock for Now (Zacks)
Dec-30-25 08:00AM	Collegium Announces the Closing of $980 Million Syndicated Credit Facility (GlobeNewswire)
Dec-28-25 11:01PM	2 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Dec-26-25 01:42PM	Here's Why Investors Should Hold Ensign Group Stock for Now (Zacks)
Dec-22-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? (Zacks)
Dec-18-25 11:35PM	3 Unpopular Stocks We Find Risky (StockStory)
05:12AM	Best Value Stocks to Buy for Dec. 18 (Zacks)
Dec-14-25 10:31PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
11:34PM	Loading…
Dec-11-25 11:34PM	1 Growth Stock Set to Flourishand 2 Facing Challenges (StockStory)
12:51PM	MOH, Aeroflow Team Up to Offer Virtual Diabetes Care in South Carolina (Zacks)
Dec-04-25 09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
09:40AM	Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:15AM	Collegium Pharmaceutical, Inc. (COLL) Hits Fresh High: Is There Still Room to Run? (Zacks)
Dec-03-25 03:45PM	Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts (Zacks)
Nov-21-25 08:04AM	Why 2025 is a Dynamic and Transformative Year for Collegium (Zacks)
Nov-19-25 08:23AM	Collegium Pharma and Entegris have been highlighted as Zacks Bull and Bear of the Day (Zacks)
04:00AM	Bull of the Day: Collegium Pharmaceutical (COLL) (Zacks)
Nov-18-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-13-25 12:36AM	5 Revealing Analyst Questions From Collegium Pharmaceutical's Q3 Earnings Call (StockStory)
Nov-12-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.60%
Nov-07-25 09:50AM	COLL Q3 Deep Dive: Jornay PM Momentum and Pain Portfolio Drive Upgraded Outlook (StockStory)
Nov-06-25 03:25PM	Why Are Collegium Pharmaceutical (COLL) Shares Soaring Today (StockStory) +13.42%
02:09PM	Loading…
02:09PM	Collegium Pharmaceutical Inc (COLL) Q3 2025 Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
09:30AM	Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Beat Estimates (Zacks)
08:09AM	Collegium Pharmaceutical (NASDAQ:COLL) Delivers Impressive Q3, Stock Jumps 12.1% (StockStory)
07:47AM	Collegium Pharmaceutical: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance (GlobeNewswire)
Nov-04-25 10:22PM	Earnings To Watch: Collegium Pharmaceutical (COLL) Reports Q3 Results Tomorrow (StockStory)
Oct-31-25 11:18AM	3 Explosive Stocks With High Short Interest (24/7 Wall St.)
Oct-30-25 10:00AM	Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-29-25 08:00AM	Paris Hilton Collaborates with Collegium Pharmaceutical to Share Her Personal ADHD Journey and Experience with Treatment (GlobeNewswire)
Oct-23-25 08:00AM	Collegium to Report Third Quarter 2025 Financial Results on November 6, 2025 (GlobeNewswire)
12:02AM	Collegium Pharmaceutical (COLL): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Oct-22-25 08:00AM	Collegium Announces Poster Presentations at the American Academy of Child & Adolescent Psychiatry and Neuroscience Education Institute Conferences (GlobeNewswire)
Oct-13-25 08:00AM	Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing (GlobeNewswire)
Oct-08-25 11:25AM	Collegium Pharmaceutical, Inc. (COLL): A Bull Case Theory (Insider Monkey)
Oct-06-25 09:51AM	ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up (Zacks)
Sep-25-25 07:19PM	Don't Overlook These 2 Highly Ranked Medical Stocks: COLL, MASI (Zacks)
12:00PM	All You Need to Know About Collegium Pharmaceutical (COLL) Rating Upgrade to Strong Buy (Zacks)
Sep-24-25 11:31PM	Branded Pharmaceuticals Stocks Q2 Highlights: Collegium Pharmaceutical (NASDAQ:COLL) (StockStory)
Sep-23-25 09:40AM	Should Value Investors Buy Collegium Pharmaceutical (COLL) Stock? (Zacks)
09:40AM	Are Medical Stocks Lagging Argenx (ARGX) This Year? (Zacks)
Sep-02-25 04:07AM	Collegium Pharmaceutical, Inc. (COLL) to Present 9 Pain Studies at PAINWeek 2025 (Insider Monkey)
Aug-29-25 05:07AM	Collegium Pharmaceutical, Inc. (COLL) Highlights Real-World Evidence at PAINWeek 2025 (Insider Monkey)
Aug-28-25 08:00AM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-25-25 08:00AM	Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting (GlobeNewswire)
Aug-14-25 01:34AM	The 5 Most Interesting Analyst Questions From Collegium Pharmaceutical's Q2 Earnings Call (StockStory)
Aug-12-25 03:25AM	COLL Q2 Deep Dive: Jornay Expansion Drives Revenue Guidance Increase, Margins Face Investment Pressure (StockStory)
Aug-11-25 09:33AM	Arm initiated, Adobe downgraded: Wall Street's top analyst calls (The Fly)
Aug-07-25 02:53PM	Collegium Pharmaceutical (NASDAQ:COLL) Exceeds Q2 Expectations, Stock Jumps 10.2% (StockStory) +10.72%
09:30AM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q2 Earnings: A Look at Key Metrics (Zacks)
08:50AM	Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates (Zacks)
07:49AM	Collegium Pharmaceutical: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Collegium Reports Second Quarter 2025 Financial Results; Raises 2025 Outlook (GlobeNewswire)
Aug-06-25 05:50PM	Inotiv, Inc. (NOTV) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Aug-05-25 11:11PM	Collegium Pharmaceutical (COLL) Q2 Earnings: What To Expect (StockStory)
10:00AM	Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-31-25 10:00AM	Collegium Pharmaceutical (COLL) Q2 Earnings Preview: What's in the Cards? (Zacks)
Jul-28-25 12:01AM	3 Reasons to Avoid COLL and 1 Stock to Buy Instead (StockStory)
Jul-25-25 09:55AM	Wall Street Analysts See a 33.91% Upside in Collegium Pharmaceutical (COLL): Can the Stock Really Move This High? (Zacks)
09:40AM	Are Investors Undervaluing Collegium Pharmaceutical (COLL) Right Now? (Zacks)
Jul-24-25 08:00AM	Collegium to Report Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jul-10-25 04:09PM	5 Hot Stocks With Summer Buybacks You Can Cash In On (MarketBeat)
Jul-07-25 08:00AM	Collegium Announces $150 Million Share Repurchase Program (GlobeNewswire)
Jul-01-25 02:42AM	Collegium Pharmaceutical Announces Share Repurchase Program Worth $25 Million (Insider Monkey)
Jun-30-25 06:24AM	5 Insightful Analyst Questions From Collegium Pharmaceutical's Q1 Earnings Call (StockStory)
Jun-10-25 04:40AM	COLL Q1 Earnings Call: ADHD Portfolio Drives Growth, Management Details Capital Deployment Priorities (StockStory)
Jun-05-25 11:31PM	Branded Pharmaceuticals Stocks Q1 In Review: Collegium Pharmaceutical (NASDAQ:COLL) Vs Peers (StockStory)
May-19-25 04:01PM	Collegium to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-25 08:05AM	Collegium Announces $25 Million Accelerated Share Repurchase Program (GlobeNewswire)
May-09-25 03:42AM	Collegium Pharmaceutical Inc (COLL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com) +5.94%
May-08-25 05:30PM	Compared to Estimates, Collegium Pharmaceutical (COLL) Q1 Earnings: A Look at Key Metrics (Zacks)
05:15PM	Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Surpass Estimates (Zacks)
04:11PM	Collegium Pharmaceutical: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Collegium Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-07-25 06:15PM	ElectroCore, Inc. (ECOR) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
05:20PM	Collegium Pharmaceutical Q1 2025 Earnings Preview (Seeking Alpha)
10:28AM	Collegium Pharmaceutical Inc (COLL) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-01-25 10:01AM	Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-28-25 12:12PM	Indivior: Trying To Break Addiction (Seeking Alpha)
09:01AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-24-25 08:00AM	Collegium to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
03:55AM	Third Avenue Small Cap Value Fund Q1 2025 Commentary (Seeking Alpha)
Apr-23-25 09:40AM	Is Collegium Pharmaceutical (COLL) Stock Undervalued Right Now? (Zacks)
Apr-16-25 02:41PM	IYH: Healthcare Dashboard For April (Seeking Alpha)
Apr-14-25 05:11AM	2 Reasons to Watch COLL and 1 to Stay Cautious (StockStory)
Apr-02-25 05:05AM	A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack (StockStory)
Apr-01-25 08:00AM	Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-27-25 08:00AM	Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine's Annual Meeting (GlobeNewswire)
Mar-26-25 07:00AM	Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board (GlobeNewswire)
Mar-18-25 03:22PM	Teva Pharmaceutical Stock Scores RS Rating Upgrade (Investor's Business Daily)

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RITA BALICE-GORDON	DIRECTOR	Dec 05 '25	Proposed Sale	47.03	3,650	171,673		Dec 17 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Option Exercise	15.90	17,600	279,840	121,213	Dec 10 04:32 PM
Dreyer Scott	EVP & Chief Commercial Officer	Dec 08 '25	Sale	48.17	17,600	847,855	103,613	Dec 10 04:32 PM
Balice-Gordon Rita J.	Director	Dec 05 '25	Sale	47.03	3,650	171,673	52,629	Dec 09 04:22 PM
Dreyer Scott	Officer	Dec 08 '25	Proposed Sale	48.17	17,600	847,855		Dec 08 04:11 PM
Fallon John A.	Director	Nov 12 '25	Option Exercise	12.41	34,853	432,578	99,487	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Sale	47.21	34,853	1,645,536	64,634	Nov 14 04:10 PM
Fallon John A.	Director	Nov 12 '25	Proposed Sale	47.21	34,853	1,645,536		Nov 12 04:29 PM
Tupper Colleen	EVP & Chief Financial Officer	Nov 06 '25	Sale	40.53	30,000	1,215,753	126,667	Nov 07 04:23 PM
Tupper Colleen	Officer	Nov 06 '25	Proposed Sale	40.53	30,000	1,215,754		Nov 06 04:11 PM
Smith Thomas B	EVP and Chief Medical Officer	Aug 29 '25	Sale	38.42	17,478	671,576	70,264	Sep 03 04:56 PM
Smith Thomas B	Officer	Aug 29 '25	Proposed Sale	38.42	17,478	671,576		Aug 29 02:12 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Option Exercise	21.34	16,389	349,741	120,002	Aug 20 04:57 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 18 '25	Sale	38.21	16,389	626,171	103,613	Aug 20 04:57 PM
SANTINI GINO	Director	Aug 15 '25	Option Exercise	13.45	15,000	201,750	100,447	Aug 19 05:10 PM
SANTINI GINO	Director	Aug 15 '25	Sale	37.19	5,405	201,018	95,042	Aug 19 05:10 PM
Dreyer Scott	Officer	Aug 18 '25	Proposed Sale	38.21	16,389	626,170		Aug 18 04:50 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Option Exercise	21.34	4,861	103,734	108,474	Aug 15 05:08 PM
Dreyer Scott	EVP & Chief Commercial Officer	Aug 13 '25	Sale	38.03	4,861	184,881	103,613	Aug 15 05:08 PM
Rubric Capital Management LP	10% Owner	Aug 13 '25	Sale	37.85	25,000	946,250	3,132,743	Aug 15 04:12 PM
SANTINI GINO	Director	Aug 15 '25	Proposed Sale	37.19	5,405	201,019		Aug 15 12:34 PM
Dreyer Scott	Officer	Aug 13 '25	Proposed Sale	38.03	4,861	184,881		Aug 13 04:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	34.36	11,659	400,641	23,129	Aug 12 05:18 PM
Heffernan Michael Thomas	Former Director	Jul 09 '25	Proposed Sale	32.17	10,328	332,269		Jul 09 04:10 PM
Heffernan Michael Thomas	Former Director	Jul 08 '25	Proposed Sale	31.38	790	24,792		Jul 08 04:19 PM
Heffernan Michael Thomas	Former Director	Jul 07 '25	Proposed Sale	31.25	14,210	444,062		Jul 07 04:43 PM
Heffernan Michael Thomas	Former Director	Jul 02 '25	Proposed Sale	30.30	25,000	757,380		Jul 02 04:50 PM
Melincoff Gwen A	Former Director	Jul 02 '25	Proposed Sale	30.29	47,082	1,425,971		Jul 02 04:35 PM
Freund John Gordon	Director	Jun 09 '25	Option Exercise	13.45	15,000	201,750	77,259	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Sale	30.62	6,601	202,149	70,658	Jun 11 05:04 PM
Freund John Gordon	Director	Jun 09 '25	Proposed Sale	30.62	6,601	202,148		Jun 09 01:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 21 '25	Sale	30.03	6,396	192,069	156,667	Mar 24 05:06 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 20 '25	Sale	30.00	1,206	36,181	163,063	Mar 24 05:06 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 21 '25	Sale	30.03	18,881	566,983	103,613	Mar 24 05:05 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 20 '25	Sale	30.00	1,927	57,811	122,494	Mar 24 05:05 PM
Tupper Colleen	Officer	Mar 21 '25	Proposed Sale	30.03	6,396	192,069		Mar 21 04:35 PM
Dreyer Scott	Officer	Mar 21 '25	Proposed Sale	30.03	18,881	566,984		Mar 21 04:21 PM
Tupper Colleen	Officer	Mar 20 '25	Proposed Sale	30.00	1,206	36,181		Mar 20 04:32 PM
Kuhlmann Shirley R.	Former Officer	Mar 20 '25	Proposed Sale	29.65	40,494	1,200,632		Mar 20 04:19 PM
Dreyer Scott	Officer	Mar 20 '25	Proposed Sale	30.00	1,927	57,811		Mar 20 04:17 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 14 '25	Sale	30.00	977	29,313	164,269	Mar 18 05:35 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 14 '25	Sale	30.00	2,255	67,661	124,421	Mar 18 05:34 PM
Tupper Colleen	Officer	Mar 14 '25	Proposed Sale	30.00	977	29,313		Mar 14 04:06 PM
Dreyer Scott	Officer	Mar 14 '25	Proposed Sale	30.00	2,255	67,661		Mar 14 03:55 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	15,387	461,672	126,676	Mar 13 04:50 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 11 '25	Sale	30.01	10,445	313,413	165,246	Mar 13 04:49 PM
Tupper Colleen	Officer	Mar 11 '25	Proposed Sale	30.01	10,445	313,413		Mar 11 04:16 PM
Dreyer Scott	Officer	Mar 11 '25	Proposed Sale	30.00	15,387	461,672		Mar 11 04:08 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 06 '25	Sale	30.00	1,949	58,470	177,195	Mar 10 04:02 PM
Tupper Colleen	EVP & Chief Financial Officer	Mar 07 '25	Sale	30.00	1,504	45,121	175,691	Mar 10 04:02 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 06 '25	Sale	30.00	3,295	98,854	144,411	Mar 10 04:01 PM
Dreyer Scott	EVP & Chief Commercial Officer	Mar 07 '25	Sale	30.00	2,348	70,446	142,063	Mar 10 04:01 PM
Dreyer Scott	Officer	Mar 07 '25	Proposed Sale	30.00	2,348	70,446		Mar 07 04:21 PM
Tupper Colleen	Officer	Mar 07 '25	Proposed Sale	30.00	1,504	45,121		Mar 07 04:13 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Option Exercise	24.03	40,000	961,200	194,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 04 '25	Sale	28.08	40,000	1,123,160	154,204	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 06 '25	Sale	28.50	26,067	742,946	108,137	Mar 06 06:48 PM
Kuhlmann Shirley R.	EVP and General Counsel	Mar 05 '25	Sale	28.03	20,000	560,528	134,204	Mar 06 06:48 PM
Tupper Colleen	Officer	Mar 06 '25	Proposed Sale	30.00	1,949	58,470		Mar 06 04:43 PM
Dreyer Scott	Officer	Mar 06 '25	Proposed Sale	30.00	3,295	98,854		Mar 06 04:31 PM
Kuhlmann Shirley R.	Officer	Mar 06 '25	Proposed Sale	28.50	26,067	742,946		Mar 06 10:42 AM
Kuhlmann Shirley R.	Officer	Mar 05 '25	Proposed Sale	28.03	20,000	560,528		Mar 05 03:03 PM
Kuhlmann Shirley R.	Officer	Mar 04 '25	Proposed Sale	28.08	40,000	1,123,160		Mar 04 04:16 PM

Open in Screener

SIBN

SI-BONE Inc

Feb 10 • 04:00PM ET

15.40

+0.01 0.06 %

Healthcare • Medical Devices • USA • NASD

Peers: GMED ATEC OFIX MDT SYK ZBH JNJ IART BAX BVS

| Held by: VTI IWM VXF IWO VTWO SCHA IHI VHT IWC DFAS

Index	RUT	P/E	-	EPS (ttm)	-0.51	Insider Own	10.65%	Shs Outstand	43.27M	Perf Week	-5.29%
Market Cap	668.23M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	-5.17%	Shs Float	38.77M	Perf Month	-24.66%
Enterprise Value	559.33M	PEG	-	EPS next Q	-0.13	Inst Own	100.76%	Short Float	6.27%	Perf Quarter	-2.35%
Income	-21.76M	P/S	3.45	EPS this Y	29.33%	Inst Trans	11.01%	Short Ratio	4.22	Perf Half Y	0.00%
Sales	193.58M	P/B	3.87	EPS next Y	7.20%	ROA	-9.43%	Short Interest	2.43M	Perf YTD	-21.91%
Book/sh	3.98	P/C	4.59	EPS next 5Y	24.06%	ROE	-12.91%	52W High	21.89 -29.65%	Perf Year	-9.78%
Cash/sh	3.36	P/FCF	-	EPS past 3/5Y	24.13% 13.67%	ROIC	-10.47%	52W Low	12.49 23.25%	Perf 3Y	-7.89%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	22.86% 19.96%	Gross Margin	79.62%	Volatility	3.52% 3.91%	Perf 5Y	-51.57%
Dividend TTM	-	EV/Sales	2.89	EPS Y/Y TTM	43.90%	Oper. Margin	-13.10%	ATR (14)	0.63	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.62	Sales Y/Y TTM	23.27%	Profit Margin	-11.24%	RSI (14)	24.42	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.97	EPS Q/Q	32.93%	SMA20	-7.27%	Beta	0.69	Target Price	25.40
Payout	-	Debt/Eq	0.21	Sales Q/Q	20.61%	SMA50	-16.49%	Rel Volume	0.57	Prev Close	15.39
Employees	349	LT Debt/Eq	0.21	Earnings	Feb 23 AMC	SMA200	-10.11%	Avg Volume	576.25K	Price	15.40
IPO	Oct 17, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	33.89% 4.30%	Trades		Volume	360,690	Change	0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Initiated	TD Cowen	Buy	$21
Aug-06-24	Reiterated	Needham	Buy	$27 → $19
Mar-28-24	Initiated	Piper Sandler	Overweight	$25
Oct-12-22	Initiated	Jefferies	Buy	$20
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight	$34
Jun-08-21	Initiated	Citigroup	Buy	$40
Mar-09-21	Reiterated	Needham	Buy	$35 → $34
Dec-16-20	Reiterated	Needham	Buy	$28 → $35
Aug-04-20	Reiterated	Needham	Buy	$22 → $24
Jun-16-20	Resumed	Cantor Fitzgerald	Overweight	$25
May-05-20	Reiterated	Needham	Buy	$27 → $22
Feb-19-20	Initiated	Needham	Buy	$27
Jan-08-20	Initiated	SunTrust	Buy	$27
Dec-18-19	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-12-18	Initiated	Morgan Stanley	Overweight	$24
Nov-12-18	Initiated	JMP Securities	Mkt Outperform	$27
Nov-12-18	Initiated	Canaccord Genuity	Buy	$25
Nov-12-18	Initiated	BofA/Merrill	Buy	$23

Show Previous Ratings

Feb-10-26 05:25PM	Electromed, Inc. (ELMD) Q2 Earnings and Revenues Top Estimates (Zacks)
Feb-02-26 04:30PM	SI-BONE To Report Fourth-Quarter and Full-Year 2025 Financial Results on February 23, 2026 (GlobeNewswire)
Jan-12-26 09:00AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 (GlobeNewswire) -12.57%
Jan-09-26 03:17AM	Jim Cramer on SI-BONE: "This is a Great, Great Speculation" (Insider Monkey)
Jan-06-26 08:31PM	Lightning Round: I'd like to be in Home Depot more than Fortune Brands, says Jim Cramer (CNBC TV)
07:20AM	Loading…
Dec-17-25 07:20AM	SI-Bone added to Conviction List, named 2026 Top Pick at Needham (TipRanks)
Dec-05-25 09:55AM	Should You Buy Si-Bone (SIBN) After Golden Cross? (Zacks)
Nov-18-25 04:09PM	SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 (GlobeNewswire)
Nov-11-25 03:02PM	Why SI-Bone Stock Was Crushing It Today (Motley Fool) +16.20%
12:02AM	SI-BONE Inc (SIBN) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... (GuruFocus.com)
Nov-10-25 05:30PM	Si-Bone (SIBN) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:34PM	Si-Bone: Q3 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance (GlobeNewswire)
Nov-06-25 05:40PM	Treace Medical Concepts (TMCI) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
Nov-04-25 05:40PM	PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:09PM	Loading…
Oct-20-25 04:09PM	SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025 (GlobeNewswire)
Aug-26-25 04:03PM	SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025 (GlobeNewswire)
Aug-14-25 01:22PM	Synergy Spine Solutions Appoints Troy Wahlenmaier as Chief Commercial Officer (PR Newswire)
Aug-05-25 03:04AM	SI-BONE Inc (SIBN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Positive ... (GuruFocus.com) -10.61%
Aug-04-25 05:45PM	Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:40PM	Si-Bone: Q2 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance (GlobeNewswire)
Jul-30-25 05:45PM	Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
Jul-29-25 04:30PM	SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 (GlobeNewswire)
Jul-14-25 04:09PM	SI-BONE To Report Second Quarter 2025 Financial Results on August 4, 2025 (GlobeNewswire)
Jul-07-25 12:00PM	All You Need to Know About Si-Bone (SIBN) Rating Upgrade to Buy (Zacks)
Jun-04-25 04:30PM	SI-BONE to Truist Securities MedTech Conference on June 17, 2025 (GlobeNewswire)
04:30PM	SI-BONE to Present at Truist Securities MedTech Conference on June 17, 2025 (GlobeNewswire)
May-28-25 04:30PM	SI-BONE to Present at Goldman Sachs 46th Global Healthcare Conference on June 10, 2025 (GlobeNewswire)
May-26-25 09:55AM	Wall Street Analysts See a 34.22% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? (Zacks)
07:30AM	Loading…
May-14-25 07:30AM	4 Recent Earnings Winners Riding Fresh Momentum in May (MarketBeat)
May-13-25 12:00PM	What Makes Si-Bone (SIBN) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-25 09:55AM	Wall Street Analysts Think Si-Bone (SIBN) Could Surge 41.21%: Read This Before Placing a Bet (Zacks)
May-06-25 04:09PM	SI-BONE To Present at BofA Securities 2025 Healthcare Conference on May 13, 2025 (GlobeNewswire) +15.44% +6.20%
08:35AM	Q1 2025 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	SI-BONE Inc (SIBN) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Positive ... (GuruFocus.com)
May-05-25 05:20PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:27PM	Si-Bone: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance (GlobeNewswire)
May-02-25 09:29AM	SI-BONE Inc (SIBN) Q1 2025: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
Apr-14-25 04:09PM	SI-BONE To Report First Quarter 2025 Financial Results on May 5, 2025 (GlobeNewswire)
Apr-10-25 10:42AM	IQVIA (IQV) Moves 8.7% Higher: Will This Strength Last? (Zacks)
Apr-08-25 07:00PM	SI-BONE, Inc.: Small-cap Developer Of Medical Implants And A Steady Revenue Grower (Seeking Alpha) +6.58%
Feb-26-25 10:01AM	SI-Bone price target raised to $24 from $20 at Needham (TipRanks)
Feb-25-25 09:03AM	Q4 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) +5.55%
02:03AM	SI-BONE Inc (SIBN) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Positive EBITDA (GuruFocus.com)
Feb-24-25 05:40PM	Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:43PM	Si-Bone: Q4 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Record Financial Results for the Fourth Quarter 2024 and Issues 2025 Guidance (GlobeNewswire)
Feb-22-25 04:21PM	SI-BONE Inc (SIBN) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-21-25 08:00AM	Bruker Appoints Laura Francis to its Board of Directors (Business Wire)
Feb-17-25 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-03-25 04:09PM	SI-BONE to Report Fourth-Quarter and Full-Year 2024 Financial Results on February 24, 2025 (GlobeNewswire) +5.29%
Jan-18-25 08:00AM	SI-Bone price target raised to $20 from $19 at Needham (TipRanks)
Jan-13-25 09:00AM	SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2024 (GlobeNewswire) +18.29%
Dec-12-24 09:55AM	Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.71%: Here's is How to Trade (Zacks)
Nov-26-24 09:55AM	Wall Street Analysts See an 83.56% Upside in Si-Bone (SIBN): Can the Stock Really Move This High? (Zacks)
Nov-20-24 04:09PM	SI-BONE To Present at Piper Sandler 36th Annual Healthcare Conference on December 4, 2024 (GlobeNewswire)
Nov-13-24 10:54AM	Q3 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -15.93%
02:18AM	SI-BONE Inc (SIBN) Q3 2024 Earnings Call Highlights: Record Revenue and Path to Profitability (GuruFocus.com)
Nov-12-24 05:25PM	Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:21PM	Si-Bone: Q3 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance (GlobeNewswire)
Nov-11-24 07:13AM	SI-BONE Inc (SIBN) Q3 2024 Earnings Report Preview: What To Look For (GuruFocus.com)
Nov-05-24 08:30AM	SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite (GlobeNewswire) +6.75%
Oct-30-24 03:35AM	Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Oct-22-24 04:09PM	SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-14-24 07:28AM	First patients are treated with Si-Bones pelvic fracture fixation device (Medical Device Network)
Oct-10-24 08:30AM	SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation (GlobeNewswire)
Aug-26-24 09:55AM	Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet (Zacks)
08:19AM	SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System (Zacks)
Aug-22-24 04:30PM	SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024 (GlobeNewswire) +11.07%
Aug-20-24 08:30AM	SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System (GlobeNewswire)
Aug-08-24 09:55AM	Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade (Zacks)
Aug-06-24 09:16AM	Q2 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024 (GlobeNewswire)
Aug-05-24 05:55PM	Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:55PM	Si-Bone: Q2 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024 (GlobeNewswire)
Jul-15-24 04:09PM	SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024 (GlobeNewswire) +8.92%
Jun-05-24 04:09PM	SI-BONE To Present at Truist Securities 2024 MedTech Conference on June 18, 2024 (GlobeNewswire)
May-07-24 11:16AM	SI-BONE, Inc. (NASDAQ:SIBN) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.29%
09:00AM	SI-BONE Expands Portfolio with the Launch of New Offering for the iFuse Bedrock Granite Implant System and Completes Inaugural Surgical Procedures (GlobeNewswire)
08:04AM	Q1 2024 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents)
03:08AM	SI-BONE Inc (SIBN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth and ... (GuruFocus.com)
May-06-24 05:25PM	Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:24PM	Si-Bone: Q1 Earnings Snapshot (Associated Press Finance)
04:09PM	SI-BONE, Inc. Reports Financial Results for the First Quarter 2024 (GlobeNewswire)
Apr-29-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
09:00AM	SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024 (GlobeNewswire)
Apr-15-24 04:09PM	SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024 (GlobeNewswire)
Mar-04-24 04:09PM	SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024 (GlobeNewswire)
Feb-27-24 06:49AM	Q4 2023 SI-BONE Inc Earnings Call (Thomson Reuters StreetEvents) -13.53%
Feb-26-24 05:38PM	Si-Bone: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	SI-BONE Inc (SIBN) Reports Record Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:09PM	SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance (GlobeNewswire)
Feb-19-24 10:00AM	Si-Bone (SIBN) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
Feb-05-24 04:09PM	SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024 (GlobeNewswire)
Jan-30-24 08:30AM	SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application (GlobeNewswire)
Jan-22-24 10:54AM	15 Small-Cap Stocks with High Potential (Insider Monkey)

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DUNN JEFFREY W	Director	Feb 02 '26	Sale	16.42	337	5,532	9,970	Feb 04 06:11 PM
DUNN JEFFREY W	Director	Jan 08 '26	Sale	21.28	20,000	425,506	80,115	Jan 12 06:07 PM
The Jeffrey W. Dunn Living Tru	Director	Jan 08 '26	Proposed Sale	21.40	60,000	1,284,000		Jan 08 04:22 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jan 02 '26	Sale	19.62	3,677	72,144	264,467	Jan 06 06:22 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Jan 02 '26	Sale	19.62	3,460	67,896	228,436	Jan 06 06:21 PM
Maheshwari Anshul	Chief Financial Officer	Jan 02 '26	Sale	19.64	5,229	102,711	180,002	Jan 06 06:20 PM
ANSHUL MAHESHWARI	Officer	Jan 02 '26	Proposed Sale	19.72	1,552	30,605		Jan 02 04:48 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Dec 18 '25	Sale	20.15	19,600	394,928	231,896	Dec 19 05:25 PM
Maheshwari Anshul	Chief Financial Officer	Dec 18 '25	Sale	20.15	18,542	373,540	185,231	Dec 19 05:24 PM
DUNN JEFFREY W	Director	Dec 08 '25	Option Exercise	4.32	1,241	5,361	11,548	Dec 11 09:37 AM
DUNN JEFFREY W	Director	Dec 08 '25	Sale	19.33	18,759	362,606	110,115	Dec 11 09:37 AM
DUNN JEFFREY W	Director	Dec 08 '25	Sale	19.33	1,241	23,988	10,307	Dec 11 09:37 AM
The Jeffrey W. Dunn Living Tru	Director	Dec 08 '25	Proposed Sale	19.68	20,000	393,600		Dec 08 04:36 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Nov 24 '25	Sale	20.00	400	8,000	251,496	Nov 26 05:21 PM
Maheshwari Anshul	Chief Financial Officer	Nov 21 '25	Sale	20.01	1,200	24,016	203,873	Nov 25 06:02 PM
Maheshwari Anshul	Chief Financial Officer	Nov 25 '25	Sale	20.00	100	2,000	203,773	Nov 25 06:02 PM
MICHAEL PISETSKY SEPARATE PROP	Officer	Nov 21 '25	Proposed Sale	18.68	20,000	373,600		Nov 21 04:47 PM
ANSHUL MAHESHWARI	Officer	Nov 21 '25	Proposed Sale	18.68	19,842	370,649		Nov 21 04:47 PM
RECUPERO ANTHONY J	President, Commercial Ops	Nov 17 '25	Sale	17.44	3,833	66,832	268,144	Nov 19 07:05 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Nov 17 '25	Sale	17.41	3,328	57,934	251,896	Nov 19 07:04 PM
Maheshwari Anshul	Chief Financial Officer	Nov 17 '25	Sale	17.43	3,460	60,297	205,073	Nov 19 07:03 PM
FRANCIS LAURA	Chief Executive Officer	Nov 17 '25	Sale	17.43	11,341	197,622	408,363	Nov 19 07:02 PM
FRANCIS LAURA	Chief Executive Officer	Nov 18 '25	Sale	17.70	5,411	95,763	351,319	Nov 19 07:02 PM
DAVID & LAURA FRANCIS JOINT RE	Director	Nov 18 '25	Proposed Sale	17.92	5,411	96,965		Nov 18 04:21 PM
FRANCIS LAURA	Chief Executive Officer	Nov 11 '25	Sale	17.06	5,411	92,307	356,730	Nov 13 04:31 PM
DUNN JEFFREY W	Director	Nov 11 '25	Option Exercise	4.32	80,000	345,600	90,307	Nov 13 04:31 PM
DUNN JEFFREY W	Director	Nov 11 '25	Sale	18.95	80,000	1,516,000	10,307	Nov 13 04:31 PM
Maheshwari Anshul	Chief Financial Officer	Nov 11 '25	Sale	18.33	2,601	47,685	208,533	Nov 13 04:31 PM
DANIEL WOLF	Director	Nov 12 '25	Proposed Sale	18.03	14,402	259,691		Nov 12 04:57 PM
The Jeffrey W. Dunn Living Tru	Director	Nov 11 '25	Proposed Sale	15.68	80,000	1,254,400		Nov 12 07:06 AM
ANSHUL MAHESHWARI	Officer	Nov 11 '25	Proposed Sale	15.68	2,601	40,784		Nov 12 07:00 AM
DAVID & LAURA FRANCIS JOINT RE	Director	Nov 11 '25	Proposed Sale	15.68	5,411	84,844		Nov 12 06:54 AM
DUNN JEFFREY W	Director	Nov 03 '25	Sale	14.80	293	4,338	10,831	Nov 04 06:51 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Oct 02 '25	Sale	14.25	3,128	44,583	255,224	Oct 06 06:10 PM
Maheshwari Anshul	Chief Financial Officer	Oct 02 '25	Sale	14.20	3,311	47,013	211,134	Oct 06 06:10 PM
RECUPERO ANTHONY J	President, Commercial Ops	Oct 02 '25	Sale	14.25	3,311	47,197	271,977	Oct 06 06:09 PM
RECUPERO ANTHONY J	President, Commercial Ops	Aug 18 '25	Sale	15.62	3,833	59,875	275,288	Aug 20 05:35 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Aug 18 '25	Sale	15.64	3,329	52,055	258,352	Aug 20 05:35 PM
Maheshwari Anshul	Chief Financial Officer	Aug 18 '25	Sale	15.57	3,461	53,881	214,445	Aug 20 05:34 PM
FRANCIS LAURA	Chief Executive Officer	Aug 18 '25	Sale	15.60	11,343	176,940	419,704	Aug 20 05:31 PM
Freund John Gordon	Director	Aug 08 '25	Sale	15.99	12,132	193,998	91,767	Aug 11 06:09 PM
DUNN JEFFREY W	Director	Aug 04 '25	Sale	17.37	293	5,091	11,647	Aug 06 05:51 PM
FRANCIS LAURA	Chief Executive Officer	Jul 07 '25	Sale	18.26	757	13,823	362,141	Jul 07 08:31 PM
Maheshwari Anshul	Chief Financial Officer	Jul 02 '25	Sale	18.34	5,005	91,811	217,078	Jul 07 08:30 PM
RECUPERO ANTHONY J	President, Commercial Ops	Jul 02 '25	Sale	18.27	3,310	60,476	279,121	Jul 07 08:29 PM
PISETSKY MICHAEL A.	SVP, Ops & Adm/Chief Legal Ofr	Jul 02 '25	Sale	18.29	3,127	57,203	261,681	Jul 07 08:29 PM
DAVID & LAURA FRANCIS JOINT RE	Director	Jul 07 '25	Proposed Sale	18.47	757	13,982		Jul 07 04:14 PM
ANSHUL MAHESHWARI	Officer	Jul 03 '25	Proposed Sale	18.43	1,695	31,239		Jul 03 01:28 PM
DUNN JEFFREY W	Director	Jun 05 '25	Sale	19.05	3,377	64,335	17,354	Jun 06 07:48 PM
FRANCIS LAURA	Chief Executive Officer	May 16 '25	Sale	19.67	12,385	243,670	495,170	May 20 07:48 PM
FRANCIS LAURA	Chief Executive Officer	May 19 '25	Sale	19.49	5,412	105,464	490,987	May 20 07:48 PM
Maheshwari Anshul	Chief Financial Officer	May 16 '25	Sale	19.76	9,585	189,399	224,507	May 20 07:47 PM
Maheshwari Anshul	Chief Financial Officer	May 19 '25	Sale	19.48	2,424	47,213	222,083	May 20 07:47 PM
RECUPERO ANTHONY J	President, Commercial Ops	May 16 '25	Sale	19.56	4,147	81,109	282,015	May 20 07:46 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	May 16 '25	Sale	19.66	3,459	68,006	264,636	May 20 07:45 PM
DAVID & LAURA FRANCIS JOINT RE	Director	May 19 '25	Proposed Sale	19.79	5,412	107,103		May 19 04:57 PM
ANSHUL MAHESHWARI	Officer	May 19 '25	Proposed Sale	19.79	2,424	47,971		May 19 04:57 PM
ANSHUL MAHESHWARI	Officer	May 16 '25	Proposed Sale	18.88	4,958	93,607		May 16 04:21 PM
Maheshwari Anshul	Chief Financial Officer	May 12 '25	Sale	19.02	4,937	93,926	232,069	May 14 08:33 PM
ANSHUL MAHESHWARI	Officer	May 12 '25	Proposed Sale	18.49	4,937	91,285		May 12 04:27 PM
FRANCIS LAURA	Chief Executive Officer	May 07 '25	Sale	17.18	38,504	661,368	302,958	May 09 07:01 PM
Maheshwari Anshul	Chief Financial Officer	May 08 '25	Sale	18.17	28,350	515,094	237,006	May 09 07:00 PM
Maheshwari Anshul	Chief Financial Officer	May 07 '25	Sale	17.00	4,937	83,939	265,356	May 09 07:00 PM
ANSHUL MAHESHWARI	Officer	May 08 '25	Proposed Sale	17.47	28,350	495,274		May 08 04:23 PM
ANSHUL MAHESHWARI	Officer	May 07 '25	Proposed Sale	16.45	4,937	81,214		May 07 04:21 PM
DAVID & LAURA FRANCIS JOINT RE	Officer	May 07 '25	Proposed Sale	16.45	38,504	633,391		May 07 04:21 PM
DUNN JEFFREY W	Director	May 01 '25	Sale	13.78	336	4,628	12,536	May 02 05:08 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	Apr 30 '25	Option Exercise	4.68	21,367	99,998	266,245	May 02 05:07 PM
Pisetsky Michael A	SVP, Ops & Adm/Chief Legal Ofr	Apr 02 '25	Sale	14.14	3,128	44,219	244,878	Apr 04 05:14 PM
RECUPERO ANTHONY J	President, Commercial Ops	Apr 02 '25	Sale	14.15	3,311	46,853	284,555	Apr 04 05:13 PM
Maheshwari Anshul	Chief Financial Officer	Apr 02 '25	Sale	14.11	3,311	46,723	270,293	Apr 04 05:12 PM
FRANCIS LAURA	Chief Executive Officer	Feb 18 '25	Sale	17.22	46,233	795,915	506,761	Feb 21 04:19 PM
Maheshwari Anshul	Chief Financial Officer	Feb 18 '25	Sale	16.86	11,180	188,518	273,604	Feb 21 04:18 PM
RECUPERO ANTHONY J	President, Commercial Ops	Feb 18 '25	Sale	16.86	9,531	160,732	287,866	Feb 21 04:17 PM
DUNN JEFFREY W	Director	Feb 18 '25	Sale	16.77	1,619	27,152	15,191	Feb 21 04:16 PM

COLL

Collegium Pharmaceutical Inc

SIBN

SI-BONE Inc

Upgrade your FINVIZ experience